Home › NDC Lookup › Ingredients › Bacitracin Zinc And Polymyxin B Sulfate › 24208-0555-55
👁️image loading
(from DailyMed)

Bacitracin Zinc and Polymyxin B Sulfate 500 [USP'U]/g; 10000 [USP'U]/g Ointment, 1 tube

by Bausch & Lomb Incorporated · 1 TUBE in 1 CARTON (24208-555-55) / 3.5 g in 1 TUBE
NDC 24208-0555-55
🏷️ FDA NDC (as labeled) 24208-555-55 billing pads the product segment with a zero
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

🆔 Identity & classification

FDA NDC (as labeled) 24208-555-55
Product NDC 24208-555
11-digit billing NDC 24208055555
NCPDP billing unit GM — per gram (weight)
RxCUI 308511
UNII 89Y4M234ES, 19371312D4
Application # ANDA064046
SPL Set ID 1b317249-30eb-4415-8a1c-cfedb4ba3549
Established class (EPC) Polymyxin-class Antibacterial
Physiologic effect Decreased Cell Wall Synthesis & Repair
Chemical class Polymyxins
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2008-04-25
Route OPHTHALMIC
Dosage form OINTMENT
Substance BACITRACIN ZINC; POLYMYXIN B SULFATE
GPI-14 86109902104200
GPI class Bacitracin-Polymyxin B
GCN Seq No 059718
GCN 25486
HICL code 003383
Ingredient (HICL) Bacitracin/Polymyxin B Sulfate
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6W
Therapeutic class — specific (HIC3) Ophthalmic Antibiotics
AHFS code 52:04.04.00
AHFS class Antibacterials (52:04)
FDB label name BACITRACIN-POLYMYXIN EYE OINT
FDB brand name Bacitracin-Polymyxin
Legend status F — Federal legend — prescription drug or device
Why two NDCs? The FDA registers this code as 24208-555-55 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 24208-0555-55. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Other antibiotics for topical use class.

Drug family (ATC) Other antibiotics for topical use, Other antibacterials, Antibiotics
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerBausch & Lomb Incorporated
Application holderBAUSCH AND LOMB INC
FDA applicationANDA064046 (ANDA)
Labeler code24208
First marketedApr 2008
Product typeHuman Prescription Drug
Portfolio92 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name BACITRACIN-POLYMYXIN EYE OINT Ingredient Bacitracin/Polymyxin B Sulfate

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $2.790 $9.76 / 3.5 g
Medicaid paysCMS SDUD · 12 mo $4.76 $16.67 / 3.5 g
Medicare drug plans payPart D · Q2 2026 $3.51 $12.27 / 3.5 g
NADAC price history (per g) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $3.536 $2.494
▼ Down 15% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Bacitracin Zinc and Polymyxin B Sulfate 500 [USP'U]/g; 10000 [USP'U]/gthis 24208-0555-55 Bausch 1 tube $2.790 — Availability likely —
Bacitracin Zinc and Polymyxin B Sulfate 500 [USP'U]/g; 10000 [USP'U]/g 50090-3274-00 A-S 1 tube — — FDA listed —
Bacitracin Zinc and Polymyxin B Sulfate 500 [USP'U]/g; 10000 [USP'U]/g 50090-7189-00 A-S 144 tubes — — FDA listed —
polycin 500 [USP'U]/g; 10000 [USP'U]/g 66267-0925-35 NuCare 3.5 g — — FDA listed —
Bacitracin Zinc and Polymyxin B Sulfate 500 [USP'U]/g; 10000 [USP'U]/g 68071-5267-03 NuCare 3.5 g — — FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2008
On the market since
Apr 2008
📍
2026
Currently FDA-listed
18 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 24208-0555-55, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
15.2K
Units reimbursed last 4 qtrs
55.5K
Gross reimbursed last 4 qtrs
$264.1K
Avg / prescription
$17.32
Avg / unit
$4.7619
Latest quarter Q4 2025
3.6KRx
Medicaid pays / g
$4.7619
gross reimbursed
vs
NADAC / g
$2.7898
acquisition cost
=
Spread
+$1.9721
+71% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
35% FFS 65% MCO
Fee-for-service · 5,375 Rx Managed care · 9,873 Rx
State Medicaid map
Alaska: no data reported AK Maine: 46 units · 3.3 per 100k residents ME Washington: no data reported WA Idaho: 42 units · 2.1 per 100k residents ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 427 units · 7.4 per 100k residents MN Wisconsin: no data reported WI Michigan: 655 units · 6.5 per 100k residents MI New York: 4,988 units · 25.5 per 100k residents NY Vermont: no data reported VT New Hampshire: 67 units · 4.8 per 100k residents NH Oregon: 494 units · 11.7 per 100k residents OR Nevada: 357 units · 11.2 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 186 units · 5.8 per 100k residents IA Illinois: 959 units · 7.6 per 100k residents IL Indiana: 932 units · 13.6 per 100k residents IN Ohio: 4,592 units · 39.0 per 100k residents OH Pennsylvania: 4,740 units · 36.6 per 100k residents PA New Jersey: 2,093 units · 22.5 per 100k residents NJ Massachusetts: 1,792 units · 25.6 per 100k residents MA California: 9,160 units · 23.5 per 100k residents CA Utah: no data reported UT Colorado: 364 units · 6.2 per 100k residents CO Nebraska: 91 units · 4.6 per 100k residents NE Missouri: 665 units · 10.7 per 100k residents MO Kentucky: 1,146 units · 25.3 per 100k residents KY West Virginia: 550 units · 31.1 per 100k residents WV Virginia: 1,813 units · 20.8 per 100k residents VA Maryland: 1,197 units · 19.4 per 100k residents MD Connecticut: 504 units · 13.9 per 100k residents CT Rhode Island: 245 units · 22.4 per 100k residents RI Arizona: 921 units · 12.4 per 100k residents AZ New Mexico: 680 units · 32.2 per 100k residents NM Kansas: 60 units · 2.0 per 100k residents KS Arkansas: 287 units · 9.4 per 100k residents AR Tennessee: 823 units · 11.5 per 100k residents TN North Carolina: 2,170 units · 20.0 per 100k residents NC South Carolina: 287 units · 5.3 per 100k residents SC Delaware: 168 units · 16.3 per 100k residents DE Oklahoma: 259 units · 6.4 per 100k residents OK Louisiana: 1,162 units · 25.4 per 100k residents LA Mississippi: 309 units · 10.5 per 100k residents MS Alabama: 476 units · 9.3 per 100k residents AL Georgia: 1,316 units · 11.9 per 100k residents GA D.C.: no data reported DC Hawaii: 179 units · 12.5 per 100k residents HI Texas: 6,038 units · 19.8 per 100k residents TX Florida: 2,237 units · 9.9 per 100k residents FL
Units reimbursed · per 100k residents
2.039.0
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Ohio 39.0 /100k
2 Pennsylvania 36.6 /100k
3 New Mexico 32.2 /100k
4 West Virginia 31.1 /100k
5 Massachusetts 25.6 /100k
6 New York 25.5 /100k
7 Louisiana 25.4 /100k
8 Kentucky 25.3 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Bacitracin Zinc and Polymyxin B Sulfate — the ingredient across all brands.

Top reported reactions

Weight Increased15
Headache13
Pain13
Wheezing13
Wound Infection13
Hypersensitivity12
Nausea12

Age at onset

Child1
Adolescent1
Adult5
Elderly2

Reporter sex

109 reports
Male · 25%
Female · 75%

Serious outcomes

Hospitalization21
Life-threatening2
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 26 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
24208-0555-55 You're viewing this 1 TUBE in 1 CARTON (24208-555-55) / 3.5 g in 1 TUBE 2008-04-25 Active

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description
🎯 Indications and Usage 26 words ▾

INDICATIONS AND USAGE For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to bacitracin zinc and polymyxin B sulfate.

⏱️ Dosage and Administration 27 words ▾

DOSAGE AND ADMINISTRATION Apply the ointment every 3 or 4 hours for 7 to 10 days, depending on the severity of the infection. FOR OPHTHALMIC USE ONLY

⛔ Contraindications 17 words ▾

CONTRAINDICATIONS This product is contraindicated in those individuals who have shown hypersensitivity to any of its components.

⚠️ Warnings 7 words ▾

WARNINGS Ophthalmic ointments may retard corneal healing.

🤒 Adverse Reactions 20 words ▾

ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🧬 Clinical Pharmacology 31 words ▾

CLINICAL PHARMACOLOGY Polymyxin B sulfate attacks gram-negative bacilli, including virtually all strains of Pseudomonas aeruginosa and Haemophilus influenzae species. Bacitracin is active against most gram-positive bacilli and cocci including hemolytic streptococci.

📦 How Supplied / Storage and Handling 88 words ▾

HOW SUPPLIED Bacitracin zinc and polymyxin B sulfate ophthalmic ointment, USP is available in tubes with an ophthalmic tip applicator in the following size: NDC 24208-555-55 - 3.5 g tube do not use Storage: Store between 15°C to 25°C (59°F to 77°F). KEEP TIGHTLY CLOSED. KEEP OUT OF REACH OF CHILDREN.

Distributed by: Bausch & Lomb Americas Inc. Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA © 2023 Bausch & Lomb Incorporated or its affiliates Revised: January 2023 9130705 (Folded) 9130605 (Flat)

📦 Storage and Handling 55 words ▾

Storage: Store between 15°C to 25°C (59°F to 77°F). KEEP TIGHTLY CLOSED. KEEP OUT OF REACH OF CHILDREN. Distributed by: Bausch & Lomb Americas Inc. Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA © 2023 Bausch & Lomb Incorporated or its affiliates Revised: January 2023 9130705 (Folded) 9130605 (Flat)

📋 Description 148 words ▾

DESCRIPTION Bacitracin zinc and polymyxin B sulfate ophthalmic ointment, USP is a sterile antimicrobial ointment formulated for ophthalmic use. Bacitracin zinc is the zinc salt of bacitracin, a mixture of related cyclic polypeptides (mainly bacitracin A) produced by the growth of an organism of the licheniformis group of Bacillus subtilis var Tracy. It has a potency of not less than 40 bacitracin units/mg.

The structural formula for bacitracin A is: Polymyxin B sulfate is the sulfate salt of polymyxin B 1 and B 2 , which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units/mg, calculated on an anhydrous basis.

The structural formulae are: Each gram contains: Actives: bacitracin zinc equal to 500 bacitracin units and polymyxin B sulfate equal to 10,000 polymyxin B units; Inactives: mineral oil and white petrolatum. bacitracinchemstructure polychemstructure

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 24208-0539-20 · Bausch 24208-0560-15 · Bausch →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.